Table 2.
Effects of CDK4/CDK6 inhibitors on the proliferation of various human mast cell lines.
| Cell Line/Cell Type | Palbociclib, IC50 | Ribociclib, IC50 | Abemaciclib, IC50 |
|---|---|---|---|
| HMC-1.1 | 92.6 ± 10.3 nM | 245.6 ± 33.4 nM | 174.5 ± 20.9 nM |
| HMC-1.2 | 296.1 ± 22.3 nM | 703.8 ± 155.0 nM | 143.8 ± 14.0 nM |
| ROSAKIT WT | 35.1 ± 2.2 nM | 262.0 ± 9.5 nM | 48.4 ± 3.5 nM |
| ROSAKIT D816V | 123.0 ± 13.1 nM | 303.3 ± 14.9 nM | 134.1 ± 5.1 nM |
| MCPV-1.1 | >10 µM | >10 µM | 1.48 ± 0.2 µM |
| MCPV-1.2 | >10 µM | >10 µM | 0.9 ± 0.07 µM |
| MCPV-1.3 | >10 µM | >10 µM | 2.83 ± 0.43 µM |
| MCPV-1.4 | >10 µM | >10 µM | 1.32 ± 0.16 µM |
Cell lines were incubated in various concentrations of palbociclib, ribociclib, or abemaciclib at 37 °C for 48 h. Then, proliferation was determined by measuring uptake of 3H-thymidine and IC50 values were calculated. Values represent the mean ± S.D. from three independent experiments. Abbreviations: IC50, half maximal inhibitory concentration; nM: nanomolar; µM, micromolar.